GRAL

GRAIL, Inc. Common Stock

32.21 USD
-0.78
2.36%
At close Feb 7, 4:00 PM EST
Pre-market
32.31
+0.10
0.31%
1 day
-2.36%
5 days
12.70%
1 month
80.25%
3 months
116.17%
6 months
82.80%
Year to date
79.74%
1 year
135.80%
5 years
135.80%
10 years
135.80%
 

About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.

Employees: 1,170

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2% more call options, than puts

Call options by funds: $3.32M | Put options by funds: $3.24M

2.29% less ownership

Funds ownership: 72.9% [Q2] → 70.6% (-2.29%) [Q3]

16% less funds holding

Funds holding: 359 [Q2] → 300 (-59) [Q3]

20% less capital invested

Capital invested by funds: $348M [Q2] → $280M (-$68.4M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

37% less first-time investments, than exits

New positions opened: 89 | Existing positions closed: 141

53% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 109

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
50%
downside
Avg. target
$16
50%
downside
High target
$16
50%
downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Morgan Stanley
Tejas Savant
33% 1-year accuracy
5 / 15 met price target
50%downside
$16
Equal-Weight
Initiated
27 Nov 2024

Financial journalist opinion

Based on 3 articles about GRAL published over the past 30 days

Positive
Investopedia
2 weeks ago
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Positive
Investopedia
2 weeks ago
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 index in recent trading.
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Neutral
PRNewsWire
3 weeks ago
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology.
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Neutral
PRNewsWire
1 month ago
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. , Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P.
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
MarketBeat
1 month ago
GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close.
GRAIL: Biotech Stock Targeting $100B Cancer Market
Positive
Investors Business Daily
2 months ago
One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's
Garmin stock, along with Ollie's Bargain Outlet, are among the best stocks to watch on the stock market today. The post One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's appeared first on Investor's Business Daily.
One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's
Neutral
Market Watch
2 months ago
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
Neutral
PRNewsWire
2 months ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Dec. 3, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 115,093 shares of GRAIL's common stock to 46 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Neutral
PRNewsWire
2 months ago
GRAIL to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. , Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences.
GRAIL to Participate in Upcoming Investor Conferences
Neutral
PRNewsWire
2 months ago
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC.
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Charts implemented using Lightweight Charts™